Safety and Tolerability of hCBE-11 in Subjects With Advanced Solid Tumors
Status:
Terminated
Trial end date:
2006-08-01
Target enrollment:
Participant gender:
Summary
This is a Phase I, open-label, dose-escalation study on subjects with advanced solid tumors.
This is the first study of hCBE-11 in humans and is designed to determine the safety and how
well patients tolerate this investigational drug. The study duration is two years with
treatment visits occurring weekly for either 4 or 8 weeks, follow-up for 8 weeks and
long-term follow-up contact every 3 months thereafter.